Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Arvinas, Inc. (ARVN) vs Autolus Therapeutics PLC Sponsored ADR (AUTL)

Arvinas, Inc. and Autolus Therapeutics PLC Sponsored ADR are both Biotechnology companies. Arvinas, Inc. and Autolus Therapeutics PLC Sponsored ADR are of similar size ($513.7M and $509.4M). Autolus Therapeutics PLC Sponsored ADR has negative trailing earnings, so its P/E is not meaningful; Arvinas, Inc. trades at 58.3×. Autolus Therapeutics PLC Sponsored ADR grew revenue faster over the last twelve months: 193.3% against −15.1%. Arvinas, Inc. has the higher net margin (2.94% vs −238.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 17 metrics below, Arvinas, Inc. leads on 14 and Autolus Therapeutics PLC Sponsored ADR on 3.

Valuation

Metric ARVN AUTL Biotechnology median
P/E 58.31 n/m 7.88
P/S 1.55 4.22 11.47
P/B 0.87 6.61 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 4.20 n/m 0.74
EV/Sales (0.24) 3.15 10.73
Earnings yield 1.72% (56.99%) (28.84%)
Free cash flow yield (42.51%) (51.29%) (23.03%)

Profitability

Metric ARVN AUTL Biotechnology median
Gross margin 97.16% 15.66% 65.16%
Operating margin (5.72%) (210.78%) 0.00%
Net margin 2.94% (238.66%) 0.00%
Free cash flow margin (65.93%) (198.26%) 0.00%
Return on equity 1.59% (133.00%) (57.72%)
Return on assets 1.17% (46.15%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ARVN AUTL Biotechnology median
Revenue growth (TTM) (15.05%) 193.29% 5.64%
EPS growth (last fiscal year) 58.84% (25.58%) —
Revenue growth, 5-year CAGR 58.93% 113.11% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ARVN AUTL Biotechnology median
Debt to equity 0.00 1.04 0.00
Current ratio 7.91 4.89 4.73
Net debt to EBITDA 5.62 1.16 0.96

Dividend

Metric ARVN AUTL Biotechnology median
Dividend yield — 22.22% 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ARVN AUTL Biotechnology median
Market cap 509.36m 513.69m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack